Laumbacher Barbara, Gu Songhai, Wank Rudolf
Immunotherapy Research Center, Pettenkoferstrasse 8, 80336 München, Germany.
J Med Case Rep. 2013 Dec 11;7:266. doi: 10.1186/1752-1947-7-266.
Despite newer treatment modalities, few patients with non-small cell lung cancer in stages IIIB and IV survive the median of one year. We present four patients with non-small cell lung cancer treated with an adjuvant therapy with cascade primed immune cells. The in vitro stimulated expression of cancer information on the patients' monocytes matures and activates T lymphocytes to destroy cancer cells. The cascade primed immune cell therapy significantly improved the quality of life and the lifespan of all four patients; thus far, three patients survived 40, 55 and 120 months, respectively; and one patient died 39 months after diagnosis.
Patient 1, stage IV (T4N2M1): The adenocarcinoma of the 67-year-old German Caucasian man infiltrated into the mediastinal lymph nodes and iliosacral bones. Chemotherapy modalities were started immediately after diagnosis of cancer, and cascade primed immune cell therapy one year later. The patient survived 39 months.Patient 2, stage IV (T3N3M1a): The 62-year-old German Caucasian woman presented with adenocarcinoma of the lower lobe with infiltrated lymph nodes of the mediastinum and malignant pleural effusion. Chemotherapy, radiation and the cascade primed immune cell therapy were administered together. The patient is still alive after 40 months.Patient 3, stage IIIB (T4N1-2M0): The 75-year-old German Caucasian woman presented with an undifferentiated tumor and a separate tumor nodule in the ipsilateral lobe. The patient received only cascade primed immune cell therapy after tumor resection and has survived for the last 55 months.Patient 4, pancoast tumor (IIIB, T3N3M0): The 77-year-old German Caucasian man presented with an undifferentiated tumor that infiltrated the lymph nodes, the clavicle, one rib and the plexus brachialis. In addition to chemotherapy and radiation, cascade primed immune cells were administered every weekday for one year. After four months, no living tumor cell was detected in the resected lung, the lymph nodes or the bone material. The patient is still alive after 120 months.
The novel adoptive cell therapy with cascade primed immune cells significantly increased the survival rate and maintained the quality of life for four patients with non-small cell lung cancer in stages IIIB and IV. Our findings indicate that tumor resection, chemotherapy and radiation appear to support the cascade primed immune cell therapy.
尽管有了更新的治疗方式，但 IIIB 期和 IV 期非小细胞肺癌患者中，很少有人能活过一年的中位数生存期。我们报告了 4 例接受级联启动免疫细胞辅助治疗的非小细胞肺癌患者。体外刺激患者单核细胞上的癌症信息表达成熟并激活 T 淋巴细胞以破坏癌细胞。级联启动免疫细胞疗法显著改善了所有 4 例患者的生活质量和寿命；迄今为止，3 例患者分别存活了 40、55 和 120 个月；1 例患者在诊断后 39 个月死亡。
患者 1，IV 期（T4N2M1）：这位 67 岁的德国白种男性腺癌浸润至纵隔淋巴结和髂骶骨。癌症诊断后立即开始化疗，一年后进行级联启动免疫细胞治疗。该患者存活了 39 个月。患者 2，IV 期（T3N3M1a）：这位 62 岁的德国白种女性表现为下叶腺癌伴纵隔淋巴结浸润和恶性胸腔积液。同时进行了化疗、放疗和级联启动免疫细胞治疗。40 个月后该患者仍然存活。患者 3，IIIB 期（T4N1 - 2M0）：这位 75 岁的德国白种女性表现为未分化肿瘤及同侧叶内一个独立的肿瘤结节。肿瘤切除后患者仅接受了级联启动免疫细胞治疗，已存活了 55 个月。患者 4，肺上沟瘤（IIIB，T3N3M0）：这位 77 岁的德国白种男性表现为未分化肿瘤，浸润至淋巴结、锁骨、一根肋骨和臂丛神经。除化疗和放疗外，工作日每天给予级联启动免疫细胞，持续一年。四个月后，在切除的肺、淋巴结或骨组织中未检测到存活的肿瘤细胞。120 个月后该患者仍然存活。
新型的级联启动免疫细胞过继性细胞疗法显著提高了 IIIB 期和 IV 期非小细胞肺癌 4 例患者的生存率并维持了生活质量。我们的研究结果表明，肿瘤切除、化疗和放疗似乎对级联启动免疫细胞疗法有支持作用。
